MODN MOBI : Information Statement Ending Dec-31-2021

GALILEO LIFE SCIENCES, INC.

(FORMERLY MODERN MOBILITY AIDS, INC.)

1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651

Phone: [phone], email: [e-mail]

QUARTERLY REPORT

For the Quarter Ended December 31, 2021

(the "Reporting Period")

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 212,693,180

As of September 30, 2021, the number of shares outstanding of our Common Stock was: 212,693,180

As of June 30, 2021, the number of shares outstanding of our Common Stock was: 212,693,180

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting

period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting

period:

Yes: ☐

No: ☒

1. Name and addresses (es)of the issuer and its predecessor (if any)

Galileo Life Sciences, Inc. (the "Company", "we", "us", or "our") was incorporated under the laws of the State of Nevada on December 19, 2007 ("Inception") under the name Glider Inc. with a business plan to sell and distribute products for mobility challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010, and to Galileo Life Sciences, Inc. on December 12, 2014. Effective October 3, 2017, the Board of Directors, pursuant to unanimous written consent of the board, authorized a change in the Company's name back to Modern Mobility Aids, Inc. On the same day, the Company filed a Certificate of Amendment with the Nevada Secretary of State amending its articles of incorporation to reflect the change in corporate name to

1 "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities.

1. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.
2. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
3. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Information and Disclosure Statement

Page 1 of 23

"Modern Mobility Aids Inc.". The Company's current status with the state of Nevada is active. The Company again has changed its name to Galileo Life Sciences, Inc. on March 12, 2021.

The Company has incorporated four wholly owned subsidiary companies: Modern Mobility Aids, Inc. (name changed to Ayden Health Inc. on May 22, 2020), an Ontario, Canada, based company on September 9, 2009 and MDRM Group (Canada) Ltd. an Ontario, Canada based company on July 14, 2011 and 2458209 Ontario Inc, an Ontario based company incorporated on March 17, 2015 and Galileo Life Sciences SA, a company incorporated in Colombia on April 6, 2021. References in this report to "Modern Mobility Aids" refer to Galileo Life Sciences, Inc. and it's all four subsidiary companies, on a consolidated basis, unless otherwise indicated or the context otherwise requires.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

• The Company's current status with the state of Nevada is active and this has remained active during the past five years as well.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

• Not applicable. (There have never been any trading suspension orders issued by the SEC related to the Company).

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

• Not applicable.

The address(es) of the issuer's principal executive office:

• The Company does not own, use, or lease any plant, properties, or other facilities. We are currently operating out of leased offices at 1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651.

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☐

• 79 Bramsteele Road, Brampton, ONTARIO L6W 3K6

Has the Company's or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: ☒

If the Company's or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

• Not Applicable.

2. Security Information

The Issuer trades on the pink sheets maintained by OTC Markets Group, Inc.

Information and Disclosure Statement

Page 2 of 23

The exact title and class of securities outstanding.

Trading symbol:	MDRM
Exact title and class of securities outstanding:	Common Stock
CUSIP:	607674108
Par or stated value:	$0.001
Total shares authorized:	1,000,000,000	as of date: Feb 11, 2022
Total shares outstanding:	212,693,180	as of date: Feb 11, 2022
Number of shares in the Public Float2:	68,104,626	as of date: Feb 11, 2022
Total number of shareholders of record:	102 as of date: Feb 11, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol:	Not Applicable
Exact title and class of securities outstanding:	Not Applicable
CUSIP:	Not Applicable
Par or stated value:	Not Applicable
Total shares authorized:	Not Applicable as of date: Not Applicable
Total shares outstanding:	Not Applicable as of date: Not Applicable

The Transfer Agent:

Vstock Transfer, LLC

18 Lafayette Place

Woodmere, NY 11598

1. 828-8436www.vstocktransfer.com

Is the Transfer Agent registered under the Exchange Act?3

Yes: ☒

No: ☐

3. Issuance History

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two

completed fiscal years and any subsequent periods: ☐

Shares Outstanding as of Second Most Recent

Fiscal Year End:

Opening Balance

Date Oct 01, 2019,

Common: 189,046,153

Preferred:

500,000

Date of

Transaction

Number of

Shares

Class of

Value

of

Were

the

Individual/

Reason

for

Restricted or

Exempti

Transaction

type

(e.g.

Issued

(or

Securities

shares

shares

Entity

Shares

share

Unrestricted

on or

new

cancelled)

issued

issued at a

were

issued

to

issuance (e.g.

as of this

Registra

issuance,

($/per

discount to

(entities must

for cash

or

filing.

tion

cancellation

share)

at

market

have

individual

debt

Type.

,

shares

Issuance

price at the

with

voting

/

conversion) -

returned to

time

of

investment

OR-

treasury)

issuance?

control

Nature

of

(Yes/No)

disclosed).

Services

Provided

1. "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.
2. To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Information and Disclosure Statement

Page 3 of 23

09/30/2020	New	500,000	Preferred	$25,000	No	Tito DiMarco	Debt	Yes	N/A
						(voting	Priv.	Conversion
						1 Shr. = 200
						common
						shares)
January 15,	New	3,647,027	Common	$3,647	Yes	-158441		Debt	Yes	N/A
2021						Ontario	Inc.	Conversion
						(1:1)
						-Thansingh
						Aneal
						-Mohamed
						Bakash
						-David A. Paul
						-Artin Ghazalian
						-Hucumchand
						Ramotar
						-Naveen	Vinnie
						Seenath
						-Yves Clement
January 15,	New	20,000,000	Common	$20,000	No	Tito DiMarco	Services	Yes	N/A
2021						and Gilbert
						Sharpe

Shares Outstanding on Date of This Report:

Ending Balance:

Date December 31, 2021, Common: 212,693,180

Preferred: 1,000,000

B. Debt Securities, Including Promissory and Convertible Notes

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note	Outstanding	Principal	Interest	Maturity	Conversion Terms (e.g. pricing	Name of	Noteholder	Reason for
Issuance	Balance ($)	Amount	Accrued	Date	mechanism	for determining	(entities	must have	Issuance
		at	($)		conversion	of instrument to	individual with voting	(e.g. Loan,
		Issuance			shares)		/ investment control	Services,
		($)					disclosed).	etc.)
Various Dates	$7,535	$28,021	$10,434	Dec 31,	Will be finalized/negotiated upon	Preston Shea	Loan
between May				2022	conversion.
& October
2015

4. Financial Statements.

A. The following financial statements were prepared in accordance with:

1. ☒ U.S. GAAP ☐ IFRS

2. The financial statements for this reporting period were prepared by (name of individual)4:

Name:	Syed Tariq Mahmood
Title:	External Accountant
Relationship to Issuer:	Independent Contractor

The financial statements of the Issuer as and for December 31, 2021, are incorporated herein as appendix 'A' for reference.

4 The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Information and Disclosure Statement

Page 4 of 23

5. Description of the Company's business, products and services.

1. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Description of Business

The Company is currently concentrating on the Telehealth, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring and other emerging opportunities in rapidly changing healthcare environment with a special focus on Canadian, Mexican and US markets. The Company aims to build a common/shared platform through which it can provide Virtual Health Care services and home medical monitoring. The Company is looking forward to acquiring controlling positions in value added companies while allowing them to keep their integrity and entrepreneurial spirit. The Company will raise additional capital to finance these acquisitions. There is a no guarantee that the funds will be secured, or the acquisitions will be done in case funds are available.

Part of the strategy is to acquire, license or invest in multiple medical technology organizations globally, build a Telehealth platform to better match patients with professionals that are appropriate for their respective ailments, and to integrate e-commerce platform to include the consultation with real-time doctors and facilitate doctor- patient conversation. The Company is taking steps to build advisory board made up of medical and regulatory professionals who will spearhead the effort to support our outreach to medical practitioner.

While management of the Company believes that the Company will be successful in its planned operating activities under its business plan and capital formation activities, there can be no assurance that it will be successful in implementation of its business plan or the formation of sufficient capital such that it will generate adequate revenues to earn a profit or sustain its operations.

B. Describe any subsidiaries, parents, or affiliated companies.

The Company has incorporated four wholly owned subsidiary companies: Modern Mobility Aids, Inc. (name changed to Ayden Health Inc. on May 22, 2020), an Ontario, Canada, based company on September 9, 2009, and MDRM Group (Canada) Ltd. an Ontario, Canada based company on July 14, 2011, and 2458209 Ontario Inc, an Ontario based company incorporated on March 17, 2015 and Galileo Life Sciences SA, a company incorporated in Colombia on April 6, 2021. References in this report to "Modern Mobility Aids" refer to Galileo Life Sciences, Inc. and it's all four subsidiary companies, on a consolidated basis, unless otherwise indicated or the context otherwise requires.

Contact information:

1968 S. Coast Hwy.

Suite1094, Laguna Beach CA 92651

Ph: 416 254 2581

C. Describe the issuers' principal products or services.

The Company is currently concentrating on the Telehealth, Virtual Care, Cardiac Monitoring, Mental Health, Tele-Monitoring, and other emerging opportunities in rapidly changing healthcare environment with a special focus on Canadian, Mexican and US markets. The Company aims to build a common/shared platform through which it can provide Virtual Health Care services and home medical monitoring.

6. Company's Facilities

The Company does not own, use, or lease any plant, properties, or other facilities. We are currently operating out of leased offices at 1968 S. Coast Hwy. Suite1094, Laguna Beach CA 92651. Management believes the current premises are sufficient for its needs at this time.

Information and Disclosure Statement

Page 5 of 23